Palvella Therapeutics (PVLA) Debt Ratio (2013 - 2014)
Palvella Therapeutics' (PVLA) quarterly Debt Ratio came in at 0.06 in Q4 2014, down 74.39% year-on-year from 0.23 in Q4 2013, and down 99.68% on a QoQ basis from 17.95 in Q3 2014.
Palvella Therapeutics (PVLA) Debt Ratio (2013 - 2014) Analysis & Trends
Palvella Therapeutics (PVLA) has 2 years of Debt Ratio data on file, last reported at 0.06 in Q4 2014.
- On a quarterly basis, Debt Ratio fell 74.39% year-over-year to 0.06 in Q4 2014; TTM through Dec 2014 was 0.06, a 74.39% decrease from a year earlier, with the FY2014 full-year figure at 0.06, down 74.39% from the prior year.
- Debt Ratio for Q4 2014 stood at 0.06, down from 17.95 in the prior quarter.
- Over the last five years, Debt Ratio for PVLA reached as high as 17.95 in Q3 2014 and fell as low as 0.06 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 1.41 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.11 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 0.06 |
| Sep 30, 2014 | 17.95 |
| Jun 30, 2014 | 0.09 |
| Mar 31, 2014 | 12.62 |
| Dec 31, 2013 | 0.23 |
| Jun 30, 2013 | 0.09 |